Acceleron Pharma (Acceleron Pharma) Shares Outstanding (Diluted Average) : 60.9 Mil (As of Sep. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Acceleron Pharma Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Acceleron Pharma's average diluted shares outstanding for the quarter that ended in Sep. 2021 was 60.9 Mil.

Acceleron Pharma Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Acceleron Pharma's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acceleron Pharma Shares Outstanding (Diluted Average) Chart

Acceleron Pharma Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Shares Outstanding (Diluted Average)

Get a 7-Day Free Trial

37.43

40.42

45.90

52.45

56.80

Acceleron Pharma Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Shares Outstanding (Diluted Average)	Get a 7-Day Free Trial															59.64	60.30	60.58	60.72	60.94

Acceleron Pharma Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

Acceleron Pharma (NAS:XLRN) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

Acceleron Pharma Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Acceleron Pharma's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.

Acceleron Pharma (Acceleron Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acceleron Pharma Inc (NAS:XLRN) » Definitions » Shares Outstanding (Diluted Average)

Comparable Companies

Traded in Other Exchanges

N/A

Address

128 Sidney Street, Cambridge, MA, USA, 02139

Website

http://www.acceleronpharma.com

Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.

Executives

Sujay Kango	officer: EVP, Chief Commercial Officer	1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Kevin F Mclaughlin	officer: SVP, CFO and Treasurer	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Adam M Veness	officer: SVP, General Counsel and Sec.	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Thomas A Mccourt	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
Habib J Dable	director, officer: CEO and President	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Terrence C Kearney	director	IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Bristol Myers Squibb Co	10 percent owner	430 E. 29TH STREET 14 FLOOR NEW YORK NY 10016
Celgene Corp /de/	10 percent owner	86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Hite	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Jean George	director	CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Kemal Malik	director	C/O ACCELERON PHARMA INC. 128 SIDNEY STREET CAMBRIDGE MA 02139